Coverage / PBLS / Trade Card

PBLS

Parabilis Medicines Inc

OPPORTUNISTIC BUY 2026-10-04 Data 8 days old USD 30.28 Healthcare - BiotechnologyAWAIT ENTRY
ACTIONABLEMethodology gates passed
59

Position levels

Currenttoday
USD 30.28
Buy <=wait / entry
USD 26.00
Trim >=take some off
USD 38.00
Thesis breakA negative or inconclusive ESMO data readout combined with termination of the Re...
-

Scenario-weighted conviction

ProbabilityScoreContribution
Bull case26%100 / 10026.0
Base case49%62 / 10030.4
Bear case25%10 / 1002.5
Weighted conviction59 / 100 - OPPORTUNISTIC BUY

Top risks

  • Strategic partnership with Regeneron via Stock Purchase Agreement for 4,166,666 shares and $50M upfront payment
  • Analyst coverage initiations with Buy ratings and price targets of $40 from Guggenheim and $45 from BofA
  • Oral presentation of updated Phase 1/2 zolucatetide clinical data at ESMO Congress 2026
Read full report →

Research is for informational purposes only. Not financial advice. All analysis reflects the date of publication.